The team’s approach rests on the hybrid-molecule concept, in which two distinct bioactive pharmacophores are covalently joined into a single chemical skeleton so that their complementary strengths reinforce one another. The first fragment is indole, a ring system found throughout nature in molecules such as tryptophan and serotonin, and in approved drugs including indomethacin and sumatriptan. Indole derivatives are known to combat oxidative damage through several routes: directly scavenging reactive oxygen species, chelating pro-oxidant metal ions, boosting endogenous antioxidant enzymes, and dampening inflammation. Because the indole core tolerates chemical modification at many positions, chemists can fine-tune its lipophilicity, solubility, and metabolic stability with relative precision.

The second fragment, thiosemicarbazide, is a sulfur- and nitrogen-rich unit whose electron-donating heteroatoms readily surrender hydrogen atoms and electrons to neutralize free radicals. It can also coordinate metal ions through its sulfur and nitrogen atoms, blocking the Fenton-like reactions that generate highly destructive hydroxyl radicals. Thiosemicarbazide derivatives have separately shown anti-inflammatory, anticancer, and antiviral activity, and the moiety often improves how candidate drugs bind their biological targets and survive metabolism. Fusing these two fragments was therefore a deliberate bet that the whole molecule would exceed the sum of its parts.

Synthesis proceeded from commercially available 3-indolepropionic acid in three steps: esterification in methanol with sulfuric acid catalysis, conversion to a hydrazide using hydrazine monohydrate, and final condensation with a series of isothiocyanates under reflux. The ten products, labeled 4a through 4j, were obtained as brown crystalline solids in yields of 51 to 62 percent and were fully verified by proton and carbon-13 nuclear magnetic resonance spectroscopy together with high-resolution mass spectrometry. For the champion compound, designated 4i, the mass spectrometric peak for its sodium adduct matched the calculated value for the formula C18H17ClN4OS to within five parts per million, confirming the proposed structure unambiguously.

Radical-scavenging assays delivered the first headline result. In the ABTS test, every derivative inhibited the radical in a concentration-dependent fashion, and at six micrograms per milliliter six of the ten compounds achieved complete scavenging. The half-maximal inhibitory concentrations spanned 0.96 to 2.21 micrograms per milliliter, several of which undercut vitamin C’s benchmark of 1.87. Compound 4i, which carries a 4-chlorophenyl substituent on the thiosemicarbazide nitrogen, led the field at 0.96 micrograms per milliliter, followed closely by the allyl-substituted 4e at 1.00. In the more demanding DPPH assay, 4i again performed best among the series at 2.95 micrograms per milliliter, approaching vitamin C’s 1.99. The pattern suggests that the para-chloro aromatic group enhances the electron distribution across the molecule in a way that favors radical capture.

To understand what such a molecule might do inside living systems, the researchers turned to computational modeling against human peroxiredoxin 5, a thioredoxin-dependent peroxidase that defends cells against oxidative damage. Molecular docking placed 4i deep in the enzyme’s catalytic pocket, anchored by conventional hydrogen bonds to the residues Gly92 and Val94, while its two aromatic rings engaged in amide-pi stacking with Gln68 and Ala90 and additional alkyl and pi-alkyl contacts with Val70 and Arg86. A 100-nanosecond molecular dynamics simulation in GROMACS then tested whether this pose would hold up under realistic thermal motion. The protein backbone and the ligand equilibrated within roughly 20 nanoseconds and thereafter fluctuated around stable averages of about 0.25 and 0.30 nanometers respectively, the protein’s radius of gyration held near 1.44 nanometers, and the complex maintained one to five hydrogen bonds throughout the trajectory. Energy decomposition singled out Val70 and Val69 as the dominant contributors to binding, and the calculated binding free energy of approximately minus 45 kilojoules per mole remained favorable across the simulation.

The authors are careful to frame these simulations as predictions rather than proof. Molecular dynamics energy estimates do not constitute experimental validation of true binding affinity, and no enzyme-level assay has yet tested whether 4i actually modulates peroxiredoxin 5’s catalytic function. Computational ADMET predictions from the Deep-PK platform, alongside a SwissADME drug-likeness analysis, suggested favorable absorption, distribution, metabolism, excretion, and safety characteristics, and the compound satisfies all four criteria of Lipinski’s rule of five, a widely used screen for oral bioavailability potential. But the researchers themselves stress that such in silico results are preliminary and cannot substitute for pharmacological or toxicological experiments.

Where the compound produced genuinely tangible results was in meat. The team dissolved 4i in edible alcohol at nominal concentrations of 0.005, 0.01, and 0.015 percent by meat weight, mixed it into minced beef tenderloin from cross-bred yellow cattle, and shaped the meat into 50-gram patties stored at 4 degrees Celsius for seven days alongside a vitamin C-treated group and an untreated control. Discoloration in fresh beef is driven largely by oxidation of myoglobin, the heme protein responsible for meat’s red hue. When the oxygenated form, oxymyoglobin, is oxidized to brown metmyoglobin, shoppers perceive the meat as stale. By day seven, metmyoglobin accounted for 76.39 percent of the myoglobin in the untreated controls, whereas patties treated with 0.015 percent 4i accumulated only 49.76 percent, a statistically significant improvement that also beat vitamin C at the same concentration.

Instrumental color measurements reinforced the visual evidence. The redness parameter, a*, declined in every group over storage, but the decline was dose-dependently blunted by 4i, leaving the highest-treated patties with the brightest redness on day seven. pH, which rises during storage as microbes proliferate and proteins break down into alkaline products, climbed less steeply in the 4i groups than in either the control or the vitamin C group, an important secondary benefit because elevated pH correlates with poorer color stability. Photographs captured the difference plainly: untreated samples began browning visibly by day three and were severely discolored by day seven, while the 0.015 percent 4i patties retained the most appealing appearance of any treatment.

The dual promise of this single small molecule, as both an antioxidant lead for drug development and a candidate protective agent for fresh meat, is what makes the study notable, but the authors are equally clear about the distance to any practical application. No residue data, acceptable daily intake values, or toxicological results exist yet for 4i, so consumer exposure and dietary risk cannot be evaluated, and comprehensive food-safety assessment is mandatory before any real-world use. The meat findings may also reflect factors beyond direct radical scavenging, including pH shifts, microbial metabolism, and oxygen availability. What the study firmly establishes is that fusing indole with thiosemicarbazide is a viable blueprint for designing potent antioxidants, and that compound 4i, with its vitamin C-surpassing ABTS activity, stable predicted binding to a human antioxidant enzyme, and demonstrable color-protecting power in beef, has earned a place in the pipeline for further structural optimization, enzyme validation, and in vivo evaluation.

Subject of Research: Synthesis and antioxidant evaluation of novel indole-thiosemicarbazide derivatives for drug leads and beef preservation

Article Title: Novel indole derivatives containing a thiosemicarbazide moiety as potential antioxidant agents for fresh beef preservation

Article References: Wang, T., Xiao, L., Ren, Y., Wu, M., Liu, Y., Tang, J., Wan, S., & Peng, J. (2026). Novel indole derivatives containing a thiosemicarbazide moiety as potential antioxidant agents for fresh beef preservation. Frontiers in Chemistry, 14, Article 1994186. https://doi.org/10.3389/fchem.2026.1994186

Image Credits: AI Generated

DOI: 10.3389/fchem.2026.1994186

Keywords: antioxidants, indole derivatives, thiosemicarbazide, free radical scavenging, molecular docking, molecular dynamics, peroxiredoxin 5, ADMET, meat preservation, myoglobin oxidation, beef color stability, medicinal chemistry

The experimental design rested on two embryonic mammalian cell lines of different origin: EBTr cells, derived from embryonic bovine trachea, and 3T3 cells, a mouse embryonic fibroblast line. These lines are standard tools in virology and toxicology laboratories, valued for their robust growth in culture and their well-characterized responses to viral infection and chemical stress. Using two cell lines from different species allowed the investigators to ask whether any observed effects were consistent across mammalian backgrounds or were instead specific to one cellular context. This cross-species comparison is particularly important in pilot studies, where the goal is to establish whether a phenomenon is general enough to justify further, more resource-intensive investigation.

To create the infections, the researchers inoculated cultures of both cell lines with a mixture of two vaccine strains of avipoxvirus, designated FK from fowl and Dessau from pigeon. Avipoxviruses are poxviruses that infect birds, and vaccine strains of these viruses are widely used in research because they can enter and express their genes in mammalian cells while producing a controlled, measurable cytopathogenic effect. By inoculating the cultures and then treating sub-populations of the infected cells with each of the two derivatives twenty-four hours after viral inoculation, the team could separate the effects of the compounds on established infection from their effects on uninfected cells. This timing is technically significant: a compound added after infection is tested for its ability to interfere with viral processes already underway inside the host cell, rather than merely blocking initial attachment or entry.

The readouts of the study were deliberately simple and complementary. The investigators determined the viral cytopathogenic effect, the visible damage that virus-infected cells sustain as replication proceeds, alongside the cytotoxic and antiviral influences of a range of concentrations of each substance. All values were assessed against control cultures of each cell line that had been neither inoculated with virus nor treated with the compounds. This dual control structure is what allows the separation of two phenomena that are otherwise easily conflated: a loss of cell viability in a treated, infected culture could reflect direct chemical toxicity, viral damage, or a combination of both. By comparing infected treated cultures against uninfected untreated controls, and by tracking viability at multiple time points after treatment, the researchers could begin to attribute observed changes to their most likely causes.

The headline finding of the study concerns the relative performance of the two derivatives. As a whole, the purine derivative aminophylline showed lower cytotoxicity but a stronger antiviral effect on virus-inoculated cells from both embryonic mammalian lines compared with the indole derivative 61-tartrat. In other words, across both the bovine EBTr and the mouse 3T3 backgrounds, aminophylline appeared to suppress the viral infection more effectively while harming the host cells less. This combination of properties is exactly what antiviral screening seeks: a compound that widens rather than narrows the gap between the concentration that inhibits the virus and the concentration that damages the cell.

A particularly informative technical observation came from comparing cell viability at the twenty-fourth and forty-eighth hours after treatment. The researchers determined a decrease in the viability of the inoculated cells from both cell types at the forty-eighth hour after treatment compared with the twenty-fourth hour. Crucially, they interpreted this result differently depending on the concentration of the derivatives. At low concentrations of the two compounds, the decline in viability was taken as evidence relevant to the antiviral comparison between them. At higher concentrations, however, the decreased viability of cells from both types was probably mainly attributable to the viral cytopathogenic effect itself rather than to the compounds. This kind of time- and concentration-dependent interpretation reflects a mature approach to cytotoxicity data, in which the same numerical change can carry different biological meanings in different experimental contexts.

From these data, the team was able to determine non-cytotoxic antiviral concentrations of each of the two derivatives that were nonetheless high enough to influence the cells of both types. Establishing such concentrations is the practical deliverable of a pilot study of this kind. It converts a qualitative observation, that a compound seems to help infected cells, into a quantitative starting point for future experiments: specific concentration ranges at which the compound can be applied without confounding the results by killing or stressing the host cells. The authors note that in this regard a strong analogy was assessed between the embryonic mammalian cells of bovine and mouse origin, meaning that the two lines behaved similarly enough that findings in one appear transferable to the other.

This cross-species consistency carries a broader implication that the authors highlight in their conclusions. The data, they write, suggest a possibility for future studies using mouse embryonic cells as a proven appropriate experimental in vitro model analogue to the respective human systems. The 3T3 mouse embryonic line is one of the most extensively characterized cell lines in biomedical research, and if antiviral and cytotoxic responses observed in EBTr cells are mirrored in 3T3 cells, researchers can design follow-up experiments on a well-standardized platform. The authors also situate their work within a wider literature on purine and indole chemistry in antiviral research, referencing work on Epstein-Barr virus, HIV, N6-methyladenosine modification of viral and cellular RNA, and epigenetic targets such as the histone methyltransferase DOT1L, whose inhibition by the compound EPZ004777 alters methylation at lysine 79 of histone H3. These references sketch the mechanistic landscape in which purine- and indole-based molecules are increasingly studied as modulators of viral and epigenetic processes.

It is worth being clear about the scope of what this pilot study does and does not establish. The experiments were performed in vitro, on vaccine strains of an avian poxvirus in rodent and bovine embryonic cells, and the compounds were tested at defined concentrations under controlled laboratory conditions. The results do not demonstrate efficacy against any human virus, nor do they establish clinical safety or dosing for either compound. Aminophylline itself is a familiar drug, long used in respiratory medicine as a bronchodilator, which gives it an established pharmacological profile in humans; however, the concentrations and mechanisms relevant to its observed antiviral activity in this cell culture system are a separate question from its classical clinical use. The value of the present work lies in defining the experimental conditions under which antiviral effects can be studied without cytotoxic confounding, and in validating a model system for that purpose.

Nevertheless, the study offers a useful methodological template for early-stage antiviral screening. By pairing two embryonic cell lines from different species, applying compounds after infection rather than before, measuring both cytopathogenic effect and cell viability over time, and interpreting viability losses in a concentration-dependent manner, the researchers assembled a picture in which aminophylline emerges as the more promising of the two derivatives for further antiviral investigation. The determination of non-cytotoxic, virus-suppressing concentrations for both aminophylline and 61-tartrat provides a concrete foundation on which subsequent studies, whether extending to additional viruses, to human cell systems, or to mechanistic dissection of how these purine and indole scaffolds interfere with viral replication, can now be built. As with all pilot studies, the findings are preliminary, but they are a documented, quantified first step rather than a speculative one.

Subject of Research: Non-cytotoxic, virus-suppressing concentrations of purine and indole derivatives in infected mammalian cell cultures

Article Title: A pilot study of non-cytotoxic, virus-suppressing concentrations of purine and indole derivatives on infected mammalian cells

Article References: Sainova, I., Kolyovska, V., Mihaylova, E., Dimitrova-Dikanarova, D., Hadjiolova, R., & Markova, T. (2026). A pilot study of non-cytotoxic, virus-suppressing concentrations of purine and indole derivatives on infected mammalian cells. BMC Pharmacology and Toxicology. https://doi.org/10.1186/s40360-026-01228-7

Image Credits: AI Generated

DOI: 10.1186/s40360-026-01228-7

Keywords: aminophylline, indole derivatives, purine derivatives, antiviral activity, cytotoxicity, avipoxvirus, embryonic mammalian cells, EBTr cells, 3T3 cells, viral cytopathogenic effect, in vitro model, pharmacology